Technical Data
R1076-05A
sRANKL (soluble RANK Ligand, Receptor Activator of NFkB Ligand)
Description:
The receptor activator of NF-kappaB ligand (RANK-L) is a recently discovered member of the TNF-ligand family involved in the regulation of the T-cell-dependent immune response, lymph node organogenesis and bone formation (1,2). RANK-L exists as both a normal, transmembrane form and a truncated, soluble form (sRANK-L), both of which can stimulate the receptor.

Applications:
Suitable for use in Western Blot. Other applications not tested.

Recommended Dilution:
Western Blot: 0.25–0.5ug/ml
Optimal dilutions to be determined by the researcher.

Positive Control:
Rat liver tissue lysate

Storage and Stability:
May be stored at 4°C for short-term only. For long-term storage and to avoid repeated freezing and thawing, add sterile glycerol (40-50%), aliquot and store at -20°C. Aliquots are stable for at least 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
TypeIsotypeCloneGrade
PabIgGAffinity Purified
SizeStorageShippingSourceHost
100ug-20°CBlue IceHumanRabbit
Concentration:
As reported
Immunogen:
Synthetic peptide corresponding to 14 amino acids near the center of human sRANK-L (Genbank No. NP_005440).
Purity:
Purified by immunoaffinity chromatography.
Form
Supplied as a liquid in PBS, 0.02% sodium azide.
Specificity:
Reacts to the middle region of human, mouse, and rat sRANK Ligand.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Wong, B.R., et al., (1997), “TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells”, J. Biol. Chem., 272:25190–25194.
2. Kong, Y.Y., et al., (1999), “OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis”, Nature, 397:315–323.
3. Weitzmann, M.N., et al., (2000), “Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines”, Blood, 96:1873–1878.
4. Bharti, A.C., et al., (2004), “Evidence that receptor activator of the nuclear factor (NF)-kappaB ligand can suppress cell proliferation and induce apoptosis through activation of a NF-kappaB-independent and TRAF6-dependent mechanism”, J. Biol. Chem., 279:6065–6076.